DSM growing in biotechnology with Microbia
September 22, 2010
HEERLEN, THE NETHERLANDS — Royal DSM N.V. has acquired Microbia, Inc., an industrial biotechnology research and development specialist, from Ironwood Pharmaceuticals, Inc. Microbia, Lexington, Mass., has developed a technology platform that allows it to use renewable sources in the production of natural carotenoids, including beta carotene and canthaxanthin, as well as nutritional products and other specialty materials.
This past January a panel of independent experts determined a bio-based beta carotene from Microbia is Generally Recognized As Safe (GRAS) for food and beverage applications.
DSM, Heerlen, will incorporate Microbia’s proprietary platform and research and development capabilities to support DSM’s development of the natural carotenoids market. Terms of the acquisition were not disclosed.
“The acquisition of Microbia represents a significant step for DSM in our strategy to accelerate our innovation activities in natural products and fermentation processes,” said Leendert Staal, president and chief executive officer of DSM Nutritional Products.
Kevin Madden, chief science officer of Microbia, said, “We are thrilled to join DSM. Being part of a large global organization and a world leader in industrial biotechnology, vitamins and carotenoid development, manufacturing and sales will expedite our ability to leverage our proprietary bio-based technology platform.
“We look forward to help accelerate DSM’s ongoing efforts to develop, produce and commercialize the next generation of nutritional ingredients and other materials that will help the food, feed and chemicals and other industries produce more innovative and sustainable products in a far more cost-effective and responsible manner.”